The District Court of The Hague granted Novo Nordisk a preliminary injunction against Ceban Ziekenhuisfarmacie B.V., stopping the sale of an unapproved compounded semaglutide nasal spray that infringes Novo Nordisk's patent. The court ruling protects patients by enforcing regulatory standards for medicine safety and efficacy, requiring Ceban to remove product listings and reimburse legal costs. Novo Nordisk emphasizes that no nasal spray form of semaglutide is approved and continues to defend its intellectual property to ensure patient safety and support medical innovation.
Novo Nordisk raised its full-year sales and profit outlook, expecting a smaller decline than previously forecasted, driven by strong GLP-1 product sales including the Wegovy pill. However, analysts remain cautious as the better-than-expected quarter ...
Novo Nordisk's U.S.-traded shares dropped over 5% after the company raised its 2026 sales and profit outlook but projected adjusted sales and operating profit to decline up to 6% or remain flat at constant exchange rates. The company reported a 3% ri...
Citi maintained a neutral rating on Novo Nordisk following the failure of its heart drug ziltevekimab in the ZEUS trial, which showed no benefit over placebo in reducing cardiovascular events. Despite this setback, the drug's expected peak sales are ...
Citi maintains a neutral rating on Novo Nordisk after its anti-inflammatory drug ziltevekimab failed to meet the primary endpoint in a heart disease trial. The trial showed no significant benefit over placebo and raised safety concerns. While Citi vi...
SpaceX will release its first public earnings report focusing on Starlink's growth, Starship development, and capital spending. Despite shares falling over 50% from their peak and trading below the IPO price, Wall Street remains optimistic with bulli...
